search query: @indexterm science / total: 202
reference: 46 / 202
| Author: | Arnst, C. |
| Title: | Blockbuster of bust |
| Journal: | Business Week
2000 : NOV 13, VOL. 3691:1021, p. 68-70 |
| Index terms: | SCIENCE BIO-TECHNOLOGY PHARMACEUTICAL INDUSTRY |
| Language: | eng |
| Abstract: | Cell Pathways Inc. CEO Robert J. Towarnicki and Chief Scientific Officer Dr. Rifat Pamukcu were understandibly wary on Oct 3. They were about to go into a meeting with investors at a UBS Warburg life sciences conference just one week after Food & Drug Administration denied approval for the company's lead drug candidate, Aptosyn. The article overviews this situation and presents the history behind the new drug and Cell Pathways Inc. |
SCIMA